-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – LZ-001 in Non-Small Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.LZ-001 in Non-Small Cell Lung CancerDrug Details:LZ-001 (TY-2136b) is under development treatment of solid tumor, central...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Metastatic Ovarian Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Plogosertib in Metastatic Ovarian Cancer Drug Details:Plogosertib is under development for the treatment of solid tumors...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – LMP-744
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LMP-744 Drug Details LMP-744 is under development for the treatment of relapsed solid tumors...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – LMP-400
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LMP-400 Drug Details Indotecan (LMP-400, NSC-743400) is under development for the treatment of relapsed...
-
Product Insights
![]()
Likelihood of Approval and Phase Transition Success Rate Model – LMP-776
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry LMP-776 Drug Details LMP-776 (Indimitecan, NSC-725776) is under development for solid tumors. It is...
-
Product Insights
![]()
Pheochromocytoma Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Pheochromocytoma is a rare, usually non-cancerous (benign) tumor that develops in cells in the center of an adrenal gland. Symptoms include high blood pressure, severe headache, tremors, shortness of breath, and constipation. The Pheochromocytoma pipeline drugs market research report provides comprehensive information on the therapeutics under development for Pheochromocytoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.